LGMD2B is a problematic disease in the field of the nervous system, with clinical performance being complex and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of LGMD2B requires a comprehensive assessment platform, including clinical performance, imaging, laboratory testing, and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment. Individualised development of treatment and management of LGMD2B treatments, typically includes drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many neurological diseases that have been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely schemes according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of LGMD2B. The platform serves a team of domestic and foreign experts in the field of neural systems related to the China International Medical Service System, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.